Farmiblastina

Farmiblastina is a pharmaceutical product containing Doxorubicin Hydrochloride, used for intravenous and intravesical applications. It is manufactured by Pfizer S.L. and is available in the EU market.

Farmiblastina, containing Doxorubicin Hydrochloride, is primarily used in the treatment of various types of cancer. It works by interfering with the growth of cancer cells, making it a key component in chemotherapy regimens. The medication is administered intravenously or intravesically, depending on the specific medical condition being treated.

Common effects of Farmiblastina may include nausea, vomiting, and fatigue. Some patients may also experience hair loss and changes in skin color. These effects can vary widely among individuals and are typically managed under medical supervision.

Farmiblastina should be handled with care, as it is a potent medication. It is important to follow the prescribed dosage and administration guidelines provided by a healthcare professional. Patients should also be aware of potential allergic reactions and report any unusual symptoms immediately.

Farmiblastina may interact with other medications, including those that affect the liver or bone marrow. It is crucial to inform healthcare providers about all current medications to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional.